Your browser doesn't support javascript.
loading
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Rimawi, Mothaffar F; Niravath, Polly; Wang, Tao; Rexer, Brent N; Forero, Andres; Wolff, Antonio C; Nanda, Rita; Storniolo, Anna M; Krop, Ian; Goetz, Matthew P; Nangia, Julie R; Jiralerspong, Sao; Pavlick, Anne; Veeraraghavan, Jamunarani; De Angelis, Carmine; Gutierrez, Carolina; Schiff, Rachel; Hilsenbeck, Susan G; Osborne, C Kent.
Afiliación
  • Rimawi MF; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. rimawi@bcm.edu.
  • Niravath P; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Wang T; Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Rexer BN; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Forero A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Wolff AC; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Nanda R; Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Storniolo AM; Vanderbilt University, Nashville, Tennessee.
  • Krop I; University of Alabama-Birmingham, Birmingham, Alabama.
  • Goetz MP; Johns Hopkins University, Baltimore, Maryland.
  • Nangia JR; University of Chicago, Chicago, Illinois.
  • Jiralerspong S; Indiana University School of Medicine, Indianapolis, Indiana.
  • Pavlick A; Dana Farber Cancer Institute, Boston, Massachusetts.
  • Veeraraghavan J; Mayo Clinic, Rochester, Minnesota.
  • De Angelis C; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Gutierrez C; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Schiff R; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Hilsenbeck SG; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Osborne CK; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Clin Cancer Res ; 26(4): 821-827, 2020 02 15.
Article en En | MEDLINE | ID: mdl-31662331
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos